Evaluation of chemotherapy response in primary bone tumors with F-18FDG positron emission tomography compared with histologically assessed tumor necrosis

被引:107
作者
Franzius, C
Sciuk, J
Brinkschmidt, C
Jürgens, H
Schober, O
机构
[1] Univ Munster Hosp, Dept Nucl Med, Munster, Germany
[2] Univ Munster Hosp, Gerhard Domagk Inst Pathol, Munster, Germany
[3] Univ Munster Hosp, Dept Pediat, Munster, Germany
[4] Univ Munster Hosp, Dept Pediat Hematol & Oncol, Munster, Germany
关键词
bone scintigraphy; fluorodeoxyglucose positron emission tomography; primary malignant bone tumors; response to chemotherapy; tumor necrosis;
D O I
10.1097/00003072-200011000-00004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study was to evaluate the potential of positron emission tomography using F-18-fluoro-2-deoxy-D-glucose (FDG PET) to assess the chemotherapy response of primary osseous tumors compared with the degree of necrosis determined histologically. Patients and Methods: Seventeen patients with primary bone tumors (11 osteosarcomas, 6 Ewing's sarcomas) were examined using FDG PET and planar bone scintigraphy before neoadjuvant chemotherapy and before surgery. Tumor response was classified histologically according to Salzer-Kuntschik (grades I-III: good response; grades IV-VI: poor response). In both imaging methods, quantification was performed using tumor to nontumor ratios (T:NT). Results: Histologically, 15 patients were classified as having good responses (grade I, n = 1; grade II, n = 6; grade III, n = 8) and two as having poor responses (grades IV and V). FDG PET showed more than a 30% decrease in T:NT ratios in all patients who had good responses. However, three of these patients had increasing bone scintigraphy T:NT ratios, and another five had decreasing ratios of less than 30%. The patients with poor responses had increasing T:NT ratios and decreasing ratios of less than 30%, respectively, using both imaging methods. Conclusions: FDG PET seems to be a promising tool for evaluating the response of primary osseous tumors to chemotherapy. In this preliminary study, FDG PET was superior to planar bone scintigraphy.
引用
收藏
页码:874 / 881
页数:8
相关论文
共 35 条
  • [1] ADLER LP, 1991, J NUCL MED, V32, P1508
  • [2] SCINTIGRAPHIC FOLLOW-UP OF OSTEOSARCOMAS DURING NEOADJUVANT CHEMOTHERAPY - RESULTS OF THE CO-OPERATIVE OSTEO-SARCOMA STUDY (COSS) OF THE SOCIETY OF PEDIATRIC ONCOLOGY
    BIELACK, S
    KNOP, J
    DELLING, G
    WINKLER, K
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 1988, 27 (06): : 237 - 241
  • [3] CALUSER CI, 1994, EUR J NUCL MED, V21, P1198
  • [4] RADIONUCLIDE BONE SCANNING OF OSTEO-SARCOMA - FALSELY EXTENDED UPTAKE PATTERNS
    CHEW, FS
    HUDSON, TM
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1982, 139 (01) : 49 - 54
  • [5] PET and [F-18]-FDG in oncology: A clinical update
    Conti, PS
    Lilien, DL
    Hawley, K
    Keppler, J
    Grafton, ST
    Bading, JR
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) : 717 - 735
  • [6] PROGNOSTIC FACTORS IN OSTEOSARCOMA - A CRITICAL-REVIEW
    DAVIS, AM
    BELL, RS
    GOODWIN, PJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) : 423 - 431
  • [7] RESPONSE OF OSTEOSARCOMA AND EWING SARCOMA TO PREOPERATIVE CHEMOTHERAPY - ASSESSMENT WITH DYNAMIC AND STATIC MR IMAGING AND SKELETAL SCINTIGRAPHY
    ERLEMANN, R
    SCIUK, J
    BOSSE, A
    RITTER, J
    KUSNIERZGLAZ, CR
    PETERS, PE
    WUISMAN, P
    [J]. RADIOLOGY, 1990, 175 (03) : 791 - 796
  • [8] PRIMARY EWING SARCOMA - FOLLOW-UP WITH GA-67 SCINTIGRAPHY
    ESTES, DN
    MAGILL, HL
    THOMPSON, EI
    HAYES, FA
    [J]. RADIOLOGY, 1990, 177 (02) : 449 - 453
  • [9] Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
    Findlay, M
    Young, H
    Cunningham, D
    Iveson, A
    Cronin, B
    Hickish, T
    Pratt, B
    Husband, J
    Flower, M
    Ott, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 700 - 708
  • [10] Garcia JR, 1996, J NUCL MED, V37, P1476